Gilead hepatitis C drug shows promise in late-stage trial

Tue Nov 27, 2012 8:06pm IST

Related Topics

Stocks

   

(Reuters) - Gilead Sciences said a late-stage trial of its experimental hepatitis C treatment showed that the virus was not detected in 78 percent of patients taking the drug, 12 weeks after completing therapy.

The trial, named Positron, was testing the drug, sofosbuvir, in patients who were unable or unwilling to take interferon -- a standard hepatitis C drug known for its unpleasant side effects.

No patient in the placebo group achieved an undetectable virus level 12 weeks after completing the therapy, Gilead said.

The safety profile of the drug was similar to that observed in prior studies, and there were few treatment discontinuations due to adverse events, Gilead said.

The company said it would submit the full data from the study for presentation at a scientific conference and will share data from additional late-stage studies in early 2013.

Gilead expects to submit its first regulatory filings for sofosbuvir by mid-2013, Chief Scientific Officer Norbert Bischofberger said.

(Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)

FILED UNDER:

Fighting Ebola

REUTERS SHOWCASE

SpiceJet Bail-Out

SpiceJet Bail-Out

Co-founder of SpiceJet seeks time to finalise rescue  Full Article 

Cybersecurity

Cybersecurity

Internet outage seen in N. Korea amid U.S. hacking dispute.  Full Article 

Tunisia Vote

Tunisia Vote

Veteran Essebsi wins Tunisia's first free presidential vote.  Full Article 

Singer Dies

Singer Dies

Joe Cocker, raspy-voiced British singer, dies at 70.  Full Article 

Cricket Update

Cricket Update

Shane Watson forced to leave Australia training by bouncer blow.  Full Article 

Jaycee Charged

Jaycee Charged

China charges Jackie Chan's son over drug offence.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device   Full Coverage